Unlock instant, AI-driven research and patent intelligence for your innovation.
Polypeptide derived from CCDC80 and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A kind of high blood pressure technology, applied in the field of biomedicine, can solve problems such as poor results, achieve good management and treatment of patients, reduce cardiac remodeling, and produce low energy consumption.
Active Publication Date: 2021-04-02
SHANGHAI CHEST HOSPITAL
View PDF4 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0006] Aiming at the above-mentioned technical problems in the prior art, the present invention provides two polypeptides derived from CCDC80 and their uses. The two polypeptides derived from CCDC80 and their uses are intended to solve the problem of drugs in the prior art for myocardial infarction caused by hypertension. Technical issues of ineffective drugs for the prevention and treatment of microvascular endothelial injury and cardiac remodeling caused by hypertension
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0024] Embodiment 1, the screening of polypeptide:
[0025] We counted groups in three motility databases (Rao, R., et al. Cell, 2014; Pourteymour, S., et al., Molecular metabolism, 2017; Parker, B., et al., Molecular & cellular proteomics ). According to the intersection analysis of the differential data of different studies, it was found that CCDC80 was differentially expressed in the three exercise databases, and the expression was significantly increased after exercise ( figure 1 A) By extracting RNA from various mouse tissues such as: heart, liver, spleen, lung, kidney, brain, fat, muscle, and blood vessels, performing reverse transcription, polymerasechain reaction, and agarosenucleotideelectrophoresis analysis, it was found that CCDC80 is specifically highly expressed in the heart and blood vessels, and has a strong correlation with cardiovascular ( figure 1 B).
[0026] CCDC80 is a secreted protein (see https: / / www.uniprot.org / , Q76M96 (CCD80_HUMAN)). After exerci...
Embodiment 2
[0031] Embodiment 2, synthesis and dilution of polypeptide:
[0032] Peptide A and Peptide B were discovered for the first time. Both peptides were synthesized by the solid-phase method by Shanghai Keyept Biotechnology Co., Ltd. according to the sequence (this method is a conventional method, so I won’t go into details here), 10mg / tube was dispensed, and sterile double Store at -20°C after diluting with distilled water.
Embodiment 3
[0033] Embodiment 3, the application of polypeptide:
[0034] 1. Peptides reduce the damage of myocardial microvascular endothelial cells caused by angiotensin II:
[0035] Under the condition of angiotensin Ⅱ stimulation, by detecting the mRNA expression level of myocardial microvascular endothelial celladhesion factor, the intervention of polypeptide A and polypeptide B on angiotensin Ⅱ-induced myocardial microvascular endothelial cell injury was evaluated.
[0036] The results showed that under the stimulation of angiotensin Ⅱ, the expression levels of the adhesion molecules of myocardial microvascular endothelial cells, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) were significantly increased (increased about 3 times), but after adding polypeptide A and polypeptide B, polypeptide A and polypeptide B can significantly reduce the expression levels of VCAM-1 and ICAM-1 ( figure 2 A, B). The difference was statistically signific...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention provides a polypeptide derived from CCDC80. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1 or 2. The invention also provides application of the polypeptide in preparation of a medicine for treating myocardial microvascular endothelial injury caused by hypertension. The invention also provides application of the polypeptide in preparation of a medicine for treatingcardiac remodeling caused by hypertension. The invention further provides application of the polypeptide in preparation of a medicine for treating hypertension. Compared with the existing polypeptidefor treating myocardial microvascular injury, the polypeptide disclosed by the invention is secreted in quantity under the physiological condition after exercise, so that the polypeptide has no obvious adverse reaction to organisms, can relieve myocardial microvascular dysfunction by increasing the exercise amount in normal organisms and organisms with early diseases, and in the middle and laterperiods, myocardial capillaries can be protected by administering the polypeptide in vitro, particularly in the case of limited motion.
Description
technical field [0001] The invention belongs to the field of biomedicine and relates to a polypeptide, specifically a polypeptide derived from CCDC80 and its application. Background technique [0002] Coronary microvascular disease (CMVD) refers to the clinical synthesis of exertional angina pectoris or objective evidence of myocardial ischemia caused by structural and functional abnormalities of precoronary arterioles and arterioles under the action of various pathogenic factors. sign. In recent years, it has been found that the incidence of CMVD is as high as 45% to 60% in people with chest pain symptoms but normal coronary angiography, and these patients have significant cardiovascular events and mortality such as myocardial ischemia, angina pectoris, and myocardial infarction. It is speculated that CMVD may be an important cause of poor prognosis. In addition, the etiology of CMVD is complex, such as: hypertension, hyperglycemia, hyperlipidemia, etc., among which damage...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More